| Literature DB >> 20721339 |
E De Greef1, T Mahler, A Janssen, H Cuypers, G Veereman-Wauters.
Abstract
Clinical management of short bowel syndrome remains a multistage process. Although PN is crucial, early introduction of enteral feeding is mandatory. We describe retrospectively 4 patients with an ultrashort bowel who could be weaned off PN on very short terms after introduction of an amino-acid-based formula (Neocate). Patient 1 had congenital short bowel with 50 cm small bowel and 30 cm colon. He had persistent diarrhoea on a semielementary formula. When Neocate was introduced he could be weaned from PN within 6 months. Patient 2 needed multiple surgical interventions because of NEC at D 27. He maintained 40 cm small bowel and an intact colon and remained PN dependent on semielemental formula. After introducing Neocate, PN could be weaned within 3 months. In the next 2 patients, Neocate was introduced as initial enteral feeding after bowel resection following antenatal midgut volvulus. Patient 3 had 20 cm small bowel and an intact colon. PN was weaned after 2 months. Patient 4 had 9 cm small bowel and an intact colon. PN was weaned after 13 months. In all patients Ileocaecal valve (ICV) was preserved. No consensus is reached on the type of formula to use for short bowel syndrome. Compared to recent data in the literature, the weaning period in these 4 patients was significantly shortened on an aminoacid based formula. The reason for this may lie in the antiallergic properties of this formula. We recommend the use of an amino-acid-based formula to induce earlier weaning of PN.Entities:
Year: 2010 PMID: 20721339 PMCID: PMC2915748 DOI: 10.1155/2010/297575
Source DB: PubMed Journal: J Nutr Metab ISSN: 2090-0724
Shows for every patient the residual small bowel length (RSBL = residual length of the small intestine measured peroperatively along the antimesenteric border), the age at the start of Neocate (N), the age of complete PN, weaning and the total time on PN. In all patients the ileocaecal valve and colon were present. m = months; d = days.
| Start N | Stop PN | Total PN | RSBL | |
|---|---|---|---|---|
| Patient 1 | 36 m | 44 m | 8 m | 50 cm |
| Patient 2 | 4 m | 7 m | 3 m | 32 cm |
| Patient 3 | 19 d | 2 m | 1 m 11 d | 20 cm |
| Patient 4 | 12 d | 13 m | 12 m 18 d | 10 cm |
Composition of the 3 commercialised elemental infant formulas and the hydrolized formula used in 2/4 patients. *Nutricia, Strombeek-Bever, Belgium, **Sandoz Nutrition Corporation, Minneapolis, US; †Abbot Nutrition, Illinois, US; ‡Nestle, Brussels, Belgium.
| Neocate* | Vivonex Pediatric** | Elecare† | Alfare‡ | |
|---|---|---|---|---|
| Kcal |
| 100 | 100 | 100 |
| Protein (g) |
| 3 | 3.1 | 3 |
| Fat (g) |
| 2.9 | 4.8 | 5.08 |
| %MCT |
| 68% | 33% | 40% |
| Carbohydrates (g) |
| 15.5 | 10.7 | 10.92 |
|
| ||||
|
| ||||
| Vit A (IU) |
| 312.5 | 273 | 350 |
| Vit D (IU) |
| 62.5 | 42 | 60 |
| Vit E (IU) |
| 3.7 | 2.1 | 2.5 |
| Vit K (mcg) |
| 5 | 6 | 8 |
| Thiamin (mcg) |
| 190 | 210 | 70 |
| Riboflavin (mcg) |
| 225 | 105 | 150 |
| Vit B6 (mcg) |
| 250 | 84.2 | 80 |
| Vit B12 (mcg) |
| 0.37 | 0.4 | 0.3 |
| Niacin (mcg) |
| 2500 | 1680 | 1000 |
| Folic Acid (mcg) |
| 25 | 29.5 | 9 |
| Pantothenic Acid (mcg) |
| 625 | 421 | 450 |
| biotin (mcg) |
| 12.5 | 4.2 | 2 |
| Vit C (mg) |
| 12.5 | 9 | 10 |
| Choline (mg) |
| 25 | 9.5 | 10 |
| Inositol (mg) |
| 7.5 | 5.1 | 5 |
|
| ||||
|
| ||||
| Calcium (mg) |
| 121.5 | 116 | 77 |
| Phosphorus (mg) |
| 100 | 84.2 | 52 |
| Magnesium (mg) |
| 25 | 8.4 | 12 |
| Iron (mg) |
| 1.25 | 1.5 | 1 |
| Zinc (mg) |
| 1.5 | 0.8 | 1 |
| Manganese (mcg) |
| 250 | 84 | 7 |
| Copper (mcg) |
| 150 | 105 | 80 |
| Iodine (mg) |
| 15 | 8.4 | 15 |
| Selenium (mcg) |
| 3.7 | 2.3 | 3.5 |
| Chromium (mcg) |
| 5.6 | 2.3 | |
| Molybdene (mcg) |
| 9.4 | 2.5 | |
| Sodium (mg) |
| 50 | 45 | 50 |
| Potassium (mg) |
| 150 | 150 | 125 |
| Chloride (mg) |
| 125 | 60 | 90 |
EN scheme used and validated in our department.
| Step 1.a | |||||
| Day | Night | ||||
| Oral stimulation (ORS) | + | + | + | + | |
| Enteral Nutrition: continuous (Neocate) | —* | —* | —* | —* | —* |
| Parenteral Nutrition: Continuous | — | — | — | — | — |
|
| |||||
| Step 1.b | |||||
| Day | Night | ||||
| Oral stimulation (ORS) | + | + | + | + | |
| Enteral Nutrition: continuous | —* | —* | —* | —* | —* |
| Parenteral Nutrition | — | ||||
|
| |||||
| Step 2 | |||||
| Day | Night | ||||
| Oral stimulation (ORS) | + | + | + | + | |
| Enteral Nutrition: continuous Neocate 20% | — | — | — | — | — |
|
| |||||
| Step 3.a | |||||
| Day | Night | ||||
| Oral Nutrition (Neocate) | — | — | — | — | |
| Enteral Nutrition: daily boluses | — | — | — | — | — |
| Nocturnal continuous | |||||
|
| |||||
| Step 3.b | |||||
| Day | Night | ||||
| Oral Nutrition (diverse) | — | — | — | — | |
| Enteral Nutrition: daily boluses (Neocate) | — | — | — | — | — |
| Nocturnal continuous | |||||
|
| |||||
| Step 4 | |||||
| Day | Night | ||||
| Oral Nutrition (diverse) | — | — | — | — | |
| Enteral Nutrition: daily boluses (Neocate) | — | — | — | — | |
| OR | |||||
| Day | Night | ||||
| Oral Nutrition (diverse) | — | — | — | — | |
| Enteral Nutrition: Nocturnal continuous | — | ||||
|
| |||||
| Step 5 | |||||
| Day | Night | ||||
| Oral Nutrition | — | — | — | — | |
|
| |||||
| Step 6 | |||||
| Diversification oral nutrition | |||||
*Progressive increase in concentration, 13%–15%–17%–20% until tolerance for total caloric requirements and growth are obtained.